Oryzon to Present its LSD1 program in Acute Leukemias at the GTC’s 2nd Epigenetics in Drug Discovery conference in Boston
Drugs from ORYZON shown to be efficacious in the treatment of Acute Leukemia
Oryzon to attend BIO-Europe Spring 2012 Conference in Amsterdam
Oryzon participates in a R&D European consortium in Parkinson’s disease
Oryzon nominates bispecific LSD1/MAOB inhibitor as drug candidate to enter preclinical development in Huntington´s Disease
ORYZON has a long tradition to collaborate with the pharma and agrofood industry in their innovative processes.
Some of our selected customers in the last years are:
